West Cancer Center & Research Institute | Strategic Alliance Partners

West Cancer Center & Research Institute is the leader in comprehensive adult cancer care led by providers to provide the most positive outcomes though research, novel therapies, advanced treatments, and cancer prevention to all patients, regardless of socioeconomic status. With over 40 years of oncology expertise, 100+ specialists, 8 locations and over 47,000 patients in 2021- West is positioned as the first choice for cancer care in the Mid-South and a national model for comprehensive care.

Connect with us:

Latest from West Cancer Center & Research Institute


Enobosarm Generates Overdue Excitement in AR+/ER+ Metastatic Breast Cancer

December 22, 2021

Lee S. Schwartzberg, MD, discusses the culmination of research with androgen-targeted agents in metastatic androgen receptor–positive, estrogen receptor–positive breast cancer and ongoing research that could lead to a paradigm shift in the second-line setting.

Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer

December 20, 2021

Dr. Schwartzberg discusses the rationale to evaluate enobosarm in androgen receptor-positive, estrogen recepetor-positive advanced breast cancer, phase 2 data with the agent, and expectations for the ongoing phase 3 ARTEST trial in this population.

Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers

February 25, 2021

Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.

Trastuzumab Deruxtecan Slated for Study in HER2+ Gastric/GEJ Cancer

February 15, 2021

Fam-trastuzumab deruxtecan-nxki is under study alone and in combination for the treatment of patients with HER2-overexpressing locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in the ongoing phase 1b/2 DESTINY-Gastric03 trial.

Lung Cancer: Chaired by Jason Porter, MD

January 26, 2021

Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of lung cancer.